Is Novo Nordisk Stock a Good Investment?
Novo Nordisk Investment Advice | NVO |
- Examine Novo Nordisk's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Novo Nordisk's leadership team and their track record. Good management can help Novo Nordisk navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Novo Nordisk's business and its evolving consumer preferences.
- Compare Novo Nordisk's performance and market position to its competitors. Analyze how Novo Nordisk is positioned in terms of product offerings, innovation, and market share.
- Check if Novo Nordisk pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Novo Nordisk's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Novo Nordisk AS stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Novo Nordisk AS is a good investment.
Sell | Buy |
Hold
Market Performance | Weakest | Details | |
Volatility | Very steady | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Novo Nordisk Stock
Researching Novo Nordisk's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company has Price/Earnings To Growth (PEG) ratio of 1.4. Novo Nordisk AS last dividend was issued on the 18th of August 2025. The entity had 2:1 split on the 20th of September 2023.
To determine if Novo Nordisk is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Novo Nordisk's research are outlined below:
| Novo Nordisk AS generated a negative expected return over the last 90 days | |
| Novo Nordisk AS has high historical volatility and very poor performance | |
| Novo Nordisk AS has 102.79 B in debt with debt to equity (D/E) ratio of 0.34, which is OK given its current industry classification. Novo Nordisk AS has a current ratio of 0.9, suggesting that it has not enough short term capital to pay financial commitments when the payables are due. Note however, debt could still be an excellent tool for Novo to invest in growth at high rates of return. | |
| Novo Nordisk AS has a poor financial position based on the latest SEC disclosures | |
| On 26th of August 2025 Novo Nordisk paid $ 0.5848 per share dividend to its current shareholders | |
| Latest headline from finance.yahoo.com: Novo Nordisk Diabetes and obesity GLP-1 portfolio still attractive says Bernstein |
Novo Nordisk uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Novo Nordisk AS. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Novo Nordisk's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 31st of January 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 31st of January 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Novo Nordisk's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Novo Nordisk's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2006-10-27 | 2006-09-30 | 0.09 | 0.1 | 0.01 | 11 | ||
2006-01-27 | 2005-12-31 | 0.18 | 0.2 | 0.02 | 11 | ||
2007-01-31 | 2006-12-31 | 0.28 | 0.25 | -0.03 | 10 | ||
2017-05-03 | 2017-03-31 | 0.265 | 0.2979 | 0.0329 | 12 | ||
2012-02-02 | 2011-12-31 | 0.26 | 0.3 | 0.04 | 15 | ||
2006-04-28 | 2006-03-31 | 0.22 | 0.18 | -0.04 | 18 | ||
2022-04-28 | 2022-03-31 | 0.4233 | 0.47 | 0.0467 | 11 | ||
2008-10-30 | 2008-09-30 | 0.37 | 0.42 | 0.05 | 13 |
Novo Nordisk Target Price Consensus
Novo target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Novo Nordisk's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 12 | Buy |
Most Novo analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Novo stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Novo Nordisk AS, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationNovo Nordisk Target Price Projection
Novo Nordisk's current and average target prices are 55.61 and 61.38, respectively. The current price of Novo Nordisk is the price at which Novo Nordisk AS is currently trading. On the other hand, Novo Nordisk's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Novo Nordisk Market Quote on 28th of September 2025
Target Price
Analyst Consensus On Novo Nordisk Target Price
Novo Nordisk Analyst Ratings
Novo Nordisk's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Novo Nordisk stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Novo Nordisk's financials, market performance, and future outlook by experienced professionals. Novo Nordisk's historical ratings below, therefore, can serve as a valuable tool for investors.Know Novo Nordisk's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Novo Nordisk is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Novo Nordisk AS backward and forwards among themselves. Novo Nordisk's institutional investor refers to the entity that pools money to purchase Novo Nordisk's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ameriprise Financial Inc | 2025-06-30 | 1.6 M |
Novo Nordisk's market capitalization trends
The company currently falls under 'Mega-Cap' category with a total capitalization of 241.93 B.Market Cap |
|
Novo Nordisk's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.28 | 0.15 | |
| Return On Capital Employed | 0.52 | 0.30 | |
| Return On Assets | 0.22 | 0.14 | |
| Return On Equity | 0.70 | 0.74 |
Determining Novo Nordisk's profitability involves analyzing its financial statements and using various financial metrics to determine if Novo Nordisk is a good buy. For example, gross profit margin measures Novo Nordisk's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Novo Nordisk's profitability and make more informed investment decisions.
Evaluate Novo Nordisk's management efficiency
Novo Nordisk AS has Return on Asset of 0.2182 % which means that on every $100 spent on assets, it made $0.2182 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.7917 %, implying that it generated $0.7917 on every 100 dollars invested. Novo Nordisk's management efficiency ratios could be used to measure how well Novo Nordisk manages its routine affairs as well as how well it operates its assets and liabilities. As of the 28th of September 2025, Return On Equity is likely to grow to 0.74, while Return On Tangible Assets are likely to drop 0.15. At this time, Novo Nordisk's Other Assets are very stable compared to the past year. As of the 28th of September 2025, Net Tangible Assets is likely to grow to about 37 B, while Return On Tangible Assets are likely to drop 0.15.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 32.22 | 33.83 | |
| Tangible Book Value Per Share | 7.27 | 3.73 | |
| Enterprise Value Over EBITDA | 20.87 | 11.23 | |
| Price Book Value Ratio | 19.38 | 20.34 | |
| Enterprise Value Multiple | 20.87 | 11.23 | |
| Price Fair Value | 19.38 | 20.34 | |
| Enterprise Value | 601.9 B | 632 B |
The leadership approach at Novo Nordisk's fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Basic technical analysis of Novo Stock
As of the 28th of September, Novo Nordisk secures the Risk Adjusted Performance of (0.03), mean deviation of 2.22, and Standard Deviation of 3.73. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Novo Nordisk AS, as well as the relationship between them.Novo Nordisk's Outstanding Corporate Bonds
Novo Nordisk issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Novo Nordisk AS uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Novo bonds can be classified according to their maturity, which is the date when Novo Nordisk AS has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Understand Novo Nordisk's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Novo Nordisk's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.12) | |||
| Mean Deviation | 2.22 | |||
| Coefficient Of Variation | (1,881) | |||
| Standard Deviation | 3.73 | |||
| Variance | 13.89 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.37) | |||
| Total Risk Alpha | (0.82) | |||
| Treynor Ratio | (0.13) | |||
| Maximum Drawdown | 26.68 | |||
| Value At Risk | (4.60) | |||
| Potential Upside | 4.77 | |||
| Skewness | (2.97) | |||
| Kurtosis | 17.01 |
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.12) | |||
| Mean Deviation | 2.22 | |||
| Coefficient Of Variation | (1,881) | |||
| Standard Deviation | 3.73 | |||
| Variance | 13.89 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.37) | |||
| Total Risk Alpha | (0.82) | |||
| Treynor Ratio | (0.13) | |||
| Maximum Drawdown | 26.68 | |||
| Value At Risk | (4.60) | |||
| Potential Upside | 4.77 | |||
| Skewness | (2.97) | |||
| Kurtosis | 17.01 |
Consider Novo Nordisk's intraday indicators
Novo Nordisk intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Novo Nordisk stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Novo Nordisk Corporate Filings
6K | 10th of September 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 27th of June 2025 Other Reports | ViewVerify | |
| 22nd of May 2025 Other Reports | ViewVerify | |
| 23rd of April 2025 Other Reports | ViewVerify |
Novo Stock media impact
There is far too much social signal, news, headlines, and media speculation about Novo Nordisk that are available to investors today. This information is accessible both publicly - through Novo Nordisk's media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Novo-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Novo Nordisk news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Novo Nordisk relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Novo Nordisk's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Novo Nordisk alpha.
Novo Nordisk Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Novo Nordisk can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Novo Nordisk AS Historical Investor Sentiment
Investor biases related to Novo Nordisk's public news can be used to forecast risks associated with an investment in Novo. The trend in average sentiment can be used to explain how an investor holding Novo can time the market purely based on public headlines and social activities around Novo Nordisk AS. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Novo Nordisk's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Novo Nordisk and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Novo Nordisk news discussions. The higher the estimate score, the more favorable the investor's outlook on Novo Nordisk.
Novo Nordisk Maximum Pain Price Across December 19th 2025 Option Contracts
Novo Nordisk's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Novo Nordisk close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Novo Nordisk's options.
Novo Nordisk Corporate Directors
| Kasim Kutay | Director | Profile | |
| Sylvie Gregoire | Independent Director | Profile | |
| Mette Jensen | Director, Employee Representative | Profile | |
| Thomas Rantzau | Director, Employee Representative | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novo Nordisk. If investors know Novo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novo Nordisk listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.327 | Dividend Share 11.65 | Earnings Share 3.93 | Revenue Per Share | Quarterly Revenue Growth 0.129 |
The market value of Novo Nordisk AS is measured differently than its book value, which is the value of Novo that is recorded on the company's balance sheet. Investors also form their own opinion of Novo Nordisk's value that differs from its market value or its book value, called intrinsic value, which is Novo Nordisk's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novo Nordisk's market value can be influenced by many factors that don't directly affect Novo Nordisk's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Novo Nordisk's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Novo Nordisk is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novo Nordisk's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.